OB_1170x120_9-14-20

attention deficit hyperactivity disorder

Impax to introduce Adderall XR generic

Impax to introduce Adderall XR generic

HAYWARD, Calif. — Impax Laboratories Inc. has received Food and Drug Administration approval for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules, mixed amphetamine product used for the treatment of attention deficit hyperactivity disorder (ADHD). Impax said Wednesday that its mixed amphetamine product, a CII controlled substance, comes in dosages of